Generic Equivalent of Lipitor Recalled Because of Wrong Doses

More than 64,000 bottles of generic Lipitor have been recalled after it was discovered that some of the pills in these containers may contain the wrong dose of the medication.  The FDA announced this generic Lipitor recall a few days ago.  The manufacturer of the drug, Ranbaxy, had already sent letters to pharmacists warning of this potential problem.  It seems that the problem arose when a pharmacist found a 20-milligram dose of generic Lipitor in a container that was supposed to contain doses of 10-milligram pills.  The pharmacist notified the company and the recall was announced soon thereafter.

This is not the first time that this issue has arisen with the generic Lipitor drug known as Atorvastatin Calcium Tablets.  In fact, this recall is seen as an expansion of the original generic Lipitor recall that was announced in August of 2012.  The company has apparently discovered additional lots of the medication that may have been affected by this problem.  Clearly, consumers are being asked to check their containers and if they are using medication affected by the recall, they should stop using it and seek a refill.

Generic Lipitor Recall Details

Anyone who is using Atorvastatin Calcium Tablets that are manufactured by Ranbaxy should take a look at their medication containers immediately.  This recall affects more than 64,600 bottles of the medication.  Details to look for on these containers include:

  • 90-count bottles of 10-milligram pills
  • Lot numbers of 2407255 or 2407256
  • An expiration date of 5/14
  • An NDC number of 63304-827-90


If your container of this medication matches this information, contact your doctor immediately to obtain a new prescription.

Other Troubles With the FDA

In addition to the fact that this most recent generic Lipitor recall stems from one in 2012, this incorrect dosage issue is not the first that Atorvastatin Calcium Tablets have encountered.  During the same year, Ranbaxy recalled 41 other lots of this medication because concerns arose that some of them could have been contaminated with glass particles.  Dozens of other medications that Ranbaxy had been selling in the United States were banned by the FDA after several serious manufacturing problems were discovered.

Aside from manufacturing and distribution problems, Ranbaxy has had other problems with the FDA.  In 2013, the company agreed to pay $500 million to settle claims made by the government that it had made false statements to the FDA.  These false statements concerned more problems with the company’s manufacturing process, and Ranbaxy agreed to continue to work to improve that process until it met FDA standards.

If you are using the medication that has been affected by this generic Lipitor recall, you need to take steps to protect yourself from potential harm.  If you have been harmed as a result of using this or any defective medication, contact the defective drugs lawyers at Parilman & Associates as soon as possible to schedule a free initial consultation.  You can do so either by emailing the firm or by calling 800-800-DRUG.